Toulouse (France), January 30th, 2017 (8:30AM CET) –VEXIM (FR0011072602 – ALVXM / PEA-PME eligible), a medical device company specializing in the minimally invasive treatment of vertebral fractures, will announce its 2016 Full-Year Results on Wednesday, 22 March, 2017 – before the market opening.
The other dates announced on the original schedule remain unchanged:
| Announcement | Date* |
| 2016 Full-Year Sales | Tuesday January 17th, 2017 |
| 2016 Full-Year Results | Wednesday March 22nd, 2017 |
| 1st quarter 2017 Sales | Wednesday April 19th, 2017 |
| Annual General Meeting | Wednesday May 24th, 2017 |
| 2017 Half-Year Sales | Tuesday July 11th, 2017 |
| 2017 Half-Year Results | Thursday September 14th, 2017 |
| 3rd quarter 2017 Sales | Thursday October 12th, 2017 |
| Financial year ended December 31 |
* Subject to modification. Press releases are distributed either before the financial markets opening, or after the closure
Financial reporting schedule:
2016 Full-Year Results: March 22nd, 20171]
About VEXIM, the innovative back microsurgery specialist
Based in Balma, near Toulouse (France), VEXIM is a medical device company created in February 2006. The company has specialized in the creation and marketing of minimally-invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of it longstanding shareholder, Truffle Capital[2] and from BPI public subsidies, VEXIM has designed and developed the SpineJack®, a unique implant capable of repairing a fractured vertebra and restoring the balance of the spinal column. The company also developed the MasterflowTM, an innovative solution for mixing and injecting orthopedic cement that enhances the accuracy of the injection and optimizes the overall surgical procedure. The company counts 66 employees, including its own sales teams in Europe and a network of international distributors.
VEXIM has been listed on Alternext Paris since May 2012. For further information, please visit www.vexim.com
SpineJack® [3], a revolutionary implant for treating Vertebral Fractures
The revolutionary aspect of the SpineJack® lies in its ability to restore a fractured vertebra to its original shape, restore the spinal column’s optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities. Thanks to a specialized range of instruments, inserting the implants into the vertebra is carried out by minimally-invasive surgery, guided by X-ray, in approximately 30 minutes, enabling the patient to be discharged shortly after surgery. The SpineJack® range consists of 3 titanium implants with 3 different diameters, thus covering 95% of vertebral fractures and all patient morphologies. SpineJack® technology benefits from the support of international scientific experts in the field of spinal surgery and worldwide patent protection through to 2029.
MasterflowTM 2, a high-performance orthopedic cement delivery system
The MasterflowTM is an innovative solution for mixing and injecting orthopedic cement that enhances the accuracy of the injection and optimizes the overall surgical procedure for treating vertebral compression fractures. The device provides a better control of the injection of biomaterials into the spine. A complement of the SpineJack®, the MasterflowTM stands out for being both easy to use and precise, particularly in its ability to stop the cement delivery instantly without inertia. The MasterflowTM contributes to reducing pain in patients. Its first sales were recorded in the U.S. in February 2015, and the system has also received the CE marking in February 2015, a mandatory conformity mark for products marketed in Europe.
| CONTACTS | |||
| VEXIM
Vincent Gardès, CEO José Da Gloria, Chief Financial Officer Tél. : +33 5 61 48 48 38
|
PRESS
ALIZE RP Caroline Carmagnol / Wendy Rigal Tél. : +33 1 44 54 36 66 Tél. : +33 6 48 82 18 94 |
||
|
Name : VEXIM ISIN code : FR0011072602 Ticker : ALVXM |
|||
